The interleukin-6-174 C allel is associated with early acute rejection in pediatric kidney allografts
lnterlökin-6 (IL-6) inflamasyon, konakçı savunması ve doku hasarında önemli rol oynayan çok işlevli bir sitokindir. Daha çok proinflamatuar sitokin olarak kabul edilmekle birlikte, son zamanlarda IL-6'nm immunsupressif rolü de saptanmıştır. Bu çalışmada, IL-6 -174 G/C promoter genotipinin, 55 böbrek nakli hastasından 14'ünde görülen akut rejeksiyona etkisi incelenmiştir. Akut rejeksiyon gözlenen 14 hastada, erken (ilk 3 ay içinde) akut rejeksiyon görülmesinin -174 C allel taşıyanlarda, taşımayanlara oranla anlamlı şekilde daha fazla olduğu bulunmuştur (%33,3 ile %10,3 p
Çocuk böbrek allograflarında erken akut rejeksiyon ile interlökin-6-174 C alleli ilişkilidir
lnterleukin-6 (IL-6) is a pleiotropic cytokine with a central role in inflammation, host defense and tissue injury. Although it is considered as predominantly proinflammatory cytokine; recently, IL-6 has been recognized as having additional immunosuppressive properties. In this study, we investigated the impact of IL-6 -174 G/C promoter genotype on acute rejection in 14 patients out of 55 kidney recipients. In 14 acute rejection presenting patients, early acute rejection (within first 3 months) was found significantly frequent in -174 C allel carriers, compared to non-carriers (33.3% vs 10.3% p<0.05). Our results imply a higher risk of early acute rejection in carriers of -174 C allel compared to non-carriers, and the relative risk of early acute rejection is 4.3 fold higher in IL-6 -174 C allel carrriers.
___
- 1. Feld LG, Stablein D, Fivush B, et al: Renal transplatation in children from 1987-1996: The annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 1997;1:146-162.
- 2. Opelz G, Mytilineos J, Scherer S, Schwarz V: Clinical implications of DNA typing in organ transplantation. The collaborative transplant study. Transplant Proc 1997; 29:1524-1527.
- 3. La Flamme AC, Pearce EJ: The absence of the IL-6 does not affect Th2 cell development in vivo, but does lead to impaired proliferation, IL-2 reseptör expression, and B cell responses. J Immunol 1999; 162:5289-5837.
- 4. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997;18:428- 432.
- 5. Xing Z, Gauldie J, Cox G et al:IL-6 is antiimflamatory cytokine required for controlling local or systemic acute inflmmatory responses. J Clin Invest 1998; 101:311-320.
- 6. Hahn AB, Kasten-Jolly JC, Constantino DM, Graffunder E, Singh TP, Shen GK, Conti DJ: TNF-α,IL-6, IFN-γ and IL-4 receptors (alpha)-chain variant Q576R: effects on renal allograft outcome. Transplantation 2001;72:660-665.
- 7. Marshall SE, McLaren AJ, Haldar NA, Bunce M, Morris PJ and Welsh KI: The impact of recipient cytokine genotype on acute rejection after renal transplantation.Transplantation 2000;70:1485-1491.
- 8. Marshall SE, McLaren AJ,Mckinney EF, Bird TG, Haldar NA, Bunce M, Morris PJ and Welsh KI: Donor cytokine genotype influences the development of acute rejection after renal transplantation. Transplantation 2001;71:469-476.
- 9. Müller-Steinhardt M, Hartel C, Müller B, Kirchner H, Fricke L: The ınterleukin 6 -174 promoter is associated with long-term kidney allograft survival. Kidney International 2002;62:1824-1827.
- 10. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for hystologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44:411-422.
- 11. Hancock WH,Whitley WD, Tullius SG et al. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993;56:643-650.
- 12. Tovey MG, Deglise-Favre A, Schoevaert D. Differential in situ expression of cytokine genes in human renal transplantation. Kidney Int 1993;43 [Suppl 39]: S129-S132.
- 13. Vandenbroecke C, Caillat-Zucman S, Legendre C, et al. Differential in situ expression of cytokines in renal allograft rejection. Transplantation. 1991; 51:602-609.
- 14. Fukatsu A, Matsuo S, Tamai H, Sakamoto N, Matsuda T, Hirano T. Distribution of interleukin-6 in normal and diseased human kidney. Lab Invest 1991;65:61-66.
- 15. Raasveld MH, Weening JJ, Kerst JM, Surachno S, ten Berge RJM. Local production of interleukin-6 during acute rejection in human renal allografts. Nephrol Dial Transplant 1993;8:75-78.
- 16. Poli F, Boschiero L, Giannoni F,Toninin M, Ancona G, Scalamogna M, Berra S and Sirchia G: TNF-α, IFN-γ, IL-6, IL-10 AND TGFβ1 gene polymorphisms in renal allografts. Transplant Proc 2001;33:348-349.
- 17. Reviron D, Dussol B, Andre M, Brunet P, Mercier P and Berland Y: TNF-α and IL-6 gene polymorphisms and rejection in kidney transplantation recipients. Transplant Proc 2001;33:350-351.
- 18. Müller-Steinhardt M, Fricke L, Müller B, Ebel B, Kirchner H and Hartel C: Cooperative influence of the IL-6 promoter polymorfisms -597,-572 and -174 on long-term kidney allograft survival. Am J Transplant 2004;4:402-408.